[1] Glaysher S, Cree I A. Cell sensitivity assays: the ATP-based tumor chemosensitivity assay[J]. Methods MolBiol, 2011, 731: 247-257. [2] Zhang J, Li H. Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay[J]. OncolLett, 2015, 9(5): 2374-2380. [3] Fehm T, Zwirner M, Wallwiener D, et al. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay[J]. BMC Cancer, 2012, 12(1): 308. [4] Vardiman J W, Thiele J, Arber D A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009,114(5): 937-951. [5] NCCN. NCCN Clinical Practice guidelines in Oncology: Acute Myeloid Leukemia, Version 1[EB/OL]. (2014-03-12) [ 2016-02- 01]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [6] Cheson B D, Bennett J M, Kopecky K J, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia[J]. J Clin Oncol. 2003. 21(24): 4642-4649. [7] 中华医学会血液学分会白血病学组. 急性髓系白血病治疗的专 家共识(第一部分)[J]. 中华血液学杂志, 2009, 30(6):429-431. [8] 中华医学会血液学分会白血病学组. 急性髓系白血病治疗的专家共识(第二部分)[J]. 中华血液学杂志, 2010, 31(1):69-70. [9] 孙黎明, 李苗, 杜淑旭,等. 细胞体外药敏试验与急性淋巴细胞白血病患儿临床治疗及预后的研究[J].实用儿科临床杂 志, 2011,26(3):174-176. [10] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays[J]. J Immunol Methods,1983, 65(1-2): 55-63. [11] Mollgard L , Tidefelt U, Sundman-Engberg B, et al. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay[J].Leuk Res, 2000, 24(5): 445-452. [12] 杨磊, 宋诸臣, 徐小红, 等. 三磷酸腺苷生物荧光法体外药敏试验指导复发或难治性非霍奇金淋巴瘤化疗的临床研究[J]. 白血病?淋巴瘤,2011, 20(10):590-593. [13] Krug U, Rolig C, Koschmieder A, et al. Complete remission and early death intensive chemotherapy in patient aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes[J]. Lancet, 2010, 376(9757): 2000-2008. [14] Faderi S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients[J]. Cancer, 2012, 118(18): 4471-4477. |